Structural stability of adenovirus type 5

Journal of Pharmaceutical Sciences

Volumn 92, Issue 3, 2003, Pages 665-678

  Rexroad, Jason ^a   Wiethoff, Christopher M ^b   Green, Anthony P ^c   Kierstead, Timothy D ^c   Scott, Miller O ^c   Middaugh, C Russell ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c Puresyn Inc   (United States)

Author keywords

Adenoviral vector; Calorimetry (DSC); Circular dichroism; Fluorescence spectroscopy; Light scattering (dynamic); Light scattering (static); Microscopy; Stability; UV Vis spectroscopy; Viral vectors

Indexed keywords

ADENOVIRUS VECTOR; FLUORESCENT DYE; SUCROSE; VIRUS DNA; VIRUS PROTEIN;

ABSORPTION SPECTROSCOPY; ADENOVIRUS 5; ARTICLE; BIOPHYSICS; CIRCULAR DICHROISM; CONCENTRATION RESPONSE; DIFFERENTIAL SCANNING CALORIMETRY; FLUORESCENCE; LIGHT ABSORPTION; LIGHT SCATTERING; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN STABILITY; PROTEIN STRUCTURE; STRUCTURE ANALYSIS; TEMPERATURE DEPENDENCE; THERMAL ANALYSIS; THERMOSTABILITY; TRANSMISSION ELECTRON MICROSCOPY; VIRUS CAPSID; VIRUS MORPHOLOGY;

EID: 0037371265     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.10340     Document Type: Article

References (41)

1. Nasz I, Adam E. 2001. Recombinant adenovirus vectors for gene therapy and clinical trials (a review). Acta Microbiol Immunol Hung 48:323-348.
2. Vorburger SA, Hunt KK. 2002. Adenoviral gene therapy. Oncologist 7:46-59.
3. Wang Y, Xiang Z, Pasquini S, Ertl HC. 1997. The use of an E1-deleted, replication-defective adenovirus recombinant expressing the rabies virus glycoprotein for early vaccination of mice against rabies virus. J Virol 71:3677-3683.
4. Hammond JM, McCoy RJ, Jansen ES, Morrissy CJ, Hodgson AL, Johnson MA. 2000. Vaccination with a single dose of a recombinant porcine adenovirus expressing the classical swine fever virus gp55 (E2) gene protects pigs against classical swine fever. Vaccine 18:1040-1050.
5. Hammond JM, Jansen ES, Morrissy CJ, Williamson MM, Hodgson AL, Johnson MA. 2001. Oral and sub-cutaneous vaccination of commercial pigs with a recombinant porcine adenovirus expressing the classical swine fever virus gp55 gene. Arch Virol 146:1787-1793.
6. Liu DW, Tsao YP, Hsieh CH, Hsieh JT, Kung JT, Chiang CL, Huang SJ, Chen SL. 2000. Induction of CD8 T cells by vaccination with recombinant adenovirus expressing human papillomavirus type 16 E5 gene reduces tumor growth. J Virol 74:9083-9089.
7. Stewart PL, Burnett RM, Cyrklaff M, Fuller SD. 1991. Image reconstruction reveals the complex molecular organization of adenovirus. Cell 67:145-154.
8. Stewart PL, Burnett RM. 1990. The structure of adenovirus. Semin Virol 1:477-487.
9. Maizel JV Jr, White DO, Scharff MD. 1968. The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology 36:115-125.
10. Tomko RP, Xu R, Philipson L. 1997. HCAR and MCAR: The human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA 94:3352-3356.
11. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW. 1997. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275:1320-1323.
12. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. 1993. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 73:309-319.
13. Russell WC, Valentine RC, Pereira HG. 1967. The effect of heat on the anatomy of the adenovirus. J Gen Virol 1:509-522.
14. Galdiero F. 1979. Adenovirus aggregation and preservation in extracellular environment. Arch Virol 59:99-105.
15. Prage L, Pettersson U, Hoglund S, Lonberg-Holm K, Philipson L. 1970. Structural proteins of adenoviruses. IV. Sequential degradation of the adenovirus type 2 virion. Virology 42:341-358.
16. Yamamoto T. 1967. The effect of ion concentration and pH on the thermal stability of a canine adenovirus. Can J Microbiol 13:1139-1149.
17. Casto BC, Hammon WM. 1966. Conditions affecting the stability of a simian adenovirus in the presence of magnesium chloride. Proc Soc Exp Biol Med 122:1216-1219.
18. Sprunck G, Wigand R. 1981. Stabilization of adenovirus infectivity against thermoinactivation by lowered ionic strength. Med Microbiol Immunol 170:37-43.
19. Croyle MA, Yu QC, Wilson JM. 2000. Development of a rapid method for the PEGylation of adenoviruses with enhanced transduction and improved stability under harsh storage conditions. Hum Gene Ther 11:1713-1722.
20. Croyle MA, Chirmule N, ZhangY, Wilson JM. 2001. "Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J Virol 75:4792-4801.
21. Croyle MA, Cheng X, Wilson JM. 2001. Development of formulations that enhance physical stability of viral vectors for gene therapy. Gene Ther 8:1281-1290.
22. Croyle MA, Roessler BJ, Davidson BL, Hilfinger JM, Amidon GL. 1998. Factors that influence stability of recombinant adenoviral preparations for human gene therapy. Pharm Dev Technol 3:373-383.
23. Gao GP, Yang Y, Wilson JM. 1996. Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J Virol 70:8934-8943.
24. Green AP, Huang JJ, Scott MO. 2002. A new scaleable method for the purification of recombinant adenovirus vectors. Hum Gene Ther 13:1921-1934.
25. Shabram PW, Giroux DD, Goudreau AM, Gregory RJ, Horn MT, Huyghe BG, Liu X, Nunnally MH, Sugarman BJ, Sutjipto S. 1997. Analytical anion-exchange HPLC of recombinant type-5 adenoviral particles. Hum Gene Ther 8:453-465.
26. Davis A, Wilson J. 1994. Vectors for gene therapy. In: Dracopoli NC, editor. Current protocols in human genetics. New York: John Wiley & Sons.
27. Grillo AO, Edwards KL, Kashi RS, Shipley KM, Hu L, Besman MJ, Middaugh CR. 2001. Conformational origin of the aggregation of recombinant human factor VIII. Biochemistry 40:586-595.
28. Kueltzo LA, Normand N, O'Hare P, Middaugh CR. 2000. Conformational lability of herpes virus protein VP22. J Biol Chem 275:33213-33221.
29. Biel SS, Gelderblom HR. 1999. Electron microscopy of viruses. In: Cann AJ, editor. Virus culture. New York: Oxford University Press Inc. pp. 129-130.
30. Oliver CJ, Shortridge KF, Belyavin G. 1976. Diffusion coefficient and molecular weight of type 5 adenovirus by photon-correlation spectroscopy. Biochim Biophys Acta 437:589-598.
31. Athappilly FK, Murali R, Rux JJ, Cai Z, Burnett RM. 1994. The refined crystal structure of hexon, the major coat protein of adenovirus type 2, at 2.9 A resolution. J Mol Biol 242:430-455.
32. Day LA, Franklin RM, Pettersson U, Philipson L. 1972. Optical properties of the hexon of adenovirus. Eur J Biochem 29:537-541.
33. Keller D, Bustamante C. 1986. Theory of the interaction of light with large inhomogeneous molecular aggregates. II. Psi-type circular dichroism. J Chem Phys 84:2972-2980.
34. Boulanger P, Loucheux-Lefevbre MH. 1982. Structure of adenovirus nucleoprotein core studied by circular dichroism and selective radiochemical labeling. Biochem Biophys Res Commun 107:470-480.
35. Watanabe K, Iso K. 1981. Quantitative analysis of chromatin structure by circular dichroism. J Mol Biol 151:143-163.
36. Wong ML, Hsu MT. 1989. Linear adenovirus DNA is organized into supercoiled domains in virus particles. Nucleic Acids Res 17:3535-3550.
37. Brown DT, Westphal M, Burlingham BT, Winterhoff U, Doerfler W. 1975. Structure and composition of the adenovirus type 2 core. J Virol 16:366-387.
38. Arakawa T, Kita Y, Carpenter JF. 1991. Protein-solvent interactions in pharmaceutical formulations. Pharm Res 8:285-291.
39. Middaugh CR. 1998. Advances in the delivery of pharmaceuticals. J Pharm Sci 87:1265-1266.
40. Volkin DB, Burke CJ, Sanyal G, Middaugh CR. 1996. Analysis of vaccine stability. Dev Biol Stand 87:135-142.
41. Nermut MV. 1984. The Architecture of adenoviruses. In: Ginsberg HS, editor. The adenoviruses. New York: Plenum Press. pp 5-64.